More on ESALF
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $35.00 |
|
|||
| Open | $35.00 | ||||
| 52 Wk High | $66.25 | ||||
| 52 Wk Low | $53.50 | ||||
| Day High | $35.00 | ||||
| Day Low | $35.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 31 | ||||
- WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Ca
- Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
- Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
- Eisai signs $388 million deal for cancer drug in Japan
- Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
- FDA accepts Eisai's LEQEMBI IQLIK application for priority review
- FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
- Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
- Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
-
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Entities mentioned with ESALF
- FDA | View Related Stories »
- Twitter | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- AdCom | View Related Stories »
- Mizuho | View Related Stories »
- Show More...
